華海藥業(600521.SH):子公司藥物臨牀試驗達到主要療效終點和所有關鍵次要療效終點
格隆匯3月4日丨華海藥業(600521.SH)公佈,下屬子公司上海華奧泰生物藥業股份有限公司(簡稱“華奧泰”)、華博生物醫藥技術(上海)有限公司(簡稱“華博生物”,系華奧泰全資子公司)自主研發的
HB0034
注射液用於治療泛發性膿皰型銀屑病急性發作的多中心、雙盲、隨機、安慰劑平行對照的關鍵性臨牀試驗達到主要療效終點和所有關鍵次要療效終點。
泛發性膿皰型銀屑病(generalized
pustular
psoriasis,GPP)是一種罕見、可危及生命的、系統性中性粒細胞性皮膚病,發作時主要表現爲全身紅斑和膿皰並伴隨全身系統性炎症症狀,如發熱、關節痛、肌痛、C
反應蛋白升高、白細胞增多等。GPP 的急性發作與死亡直接相關,若不及時控制可能會導致敗血癥和多系統器官衰竭,危及生命,因此治療 GPP
的當務之急便是控制急性發作,亟須快速控制急性發作的治療手段。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.